03:53 AM EDT, 05/02/2024 (MT Newswires) -- Jazz Pharmaceuticals ( JAZZ ) reported Q1 adjusted earnings late Wednesday of $2.68 per diluted share, down from $3.95 a year earlier.

Analysts polled by Capital IQ expected $4.18.

Revenue for the quarter ended March 31 was about $902 million, up from $892.8 million a year earlier. Analysts surveyed by Capital IQ expected $954.3 million.

The company reiterated its full-year 2024 outlook for adjusted EPS of $18.15 to $19.35 and revenue of $4 billion to $4.2 billion. Analysts polled by Capital IQ expect normalized EPS of $18.65 on revenue of $4.07 billion.

Price: 107.00, Change: -3.31, Percent Change: -3.00